| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
AMEX: IOX |
| Security Type |
Common Stock |
| Lead Underwriter |
EVEREN Securities Inc |
| Days In Registration |
202 |
| Date Filed |
3-Oct-1997 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Develops, manufactures and wholesale controllable drug delivery systems using iontophoretic technology; Iontophoresis is a non-evasive method of enhancing and contolling the supoport of water-soluble ionic drugs into and through the skin using a low level electrical current |
| Revenue |
$9.3M |
| Net Income |
-$14M |
| Shares Outstanding (post-offering) |
6.5M |
| Chief Executive Officer |
Ned M. Weinshenker, Ph.D |
| Number of Employees |
80 |
|
| Original Filing Information |
| US |
| Shares Filed |
1.7M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
1.7M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
255.0K |
| File Amount |
$20.4M |
| File Price Range |
$13.00 - $11.00 |
| File Mid Price |
$12.00 |
Current Filing Information
(Amended 23-Apr-1998) |
|
US |
|
Shares Filed |
1.7M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
1.7M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$13.6M |
| · % Change from Original |
-33.33 |
| File Price Range |
$8.50 - $7.50 |
| File Mid Price |
$8.00 |
|
